Last update:

Clinical pharmacology news

GLP-1 agonist drugs show digestive side effects but may help fight infections

Originally developed to treat diabetes, a class of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now stepping into the spotlight as weight loss drugs. A recent umbrella review draws attention to ...

First-in-class molecules dial down inflammation without compromising immunity

Scripps Research scientists have developed a new class of drug compounds that reduce harmful inflammation while leaving the body's ability to fight infections intact—a long-sought goal in treating autoimmune diseases. The ...

Zebrafish reveal new insights into the biology of autism

In recent decades, the zebrafish has become one of the most valuable model organisms in scientific research. For a variety of reasons, including their genetic similarities to humans, these tiny tropical fish have helped researchers ...

New pill could change plaque psoriasis treatment

Folks with severe plaque psoriasis often have to choose between convenient pills that don't work very well or highly effective injections that come with the hassle of needles. That trade-off may soon change. New clinical ...

FDA approves new weight loss pill in record time

A new daily pill to help with weight loss has been approved by the U.S. Food and Drug Administration (FDA), and it moved through review faster than most drugs in recent years.

Poison centers see jump in kava calls

Calls to poison centers about kava—a drug found in drinks marketed as a healthy alternative to alcoholic beverages—rose 383% between 2011 and 2025, according to a new UVA Health study. The findings have been published in ...

Probing a paradoxical drug response for irregular heartbeat

Irregular heartbeat, or arrhythmia, can be treated with various procedures or medication, but not all medications work for all patients. In fact, one arrhythmia medication can actually cause arrhythmia in people with a common ...

Boron agents reach previously untreatable tumors

Boron agents termed GluBs, developed by Science Tokyo researchers, have overcome a key limitation in cancer therapy by entering tumor cells through a pathway that standard drugs cannot use. The GluBs target ASCT2, a transporter ...

New mRNA platform remains effective even in aging and obesity

Since the COVID-19 pandemic, mRNA vaccines have gained attention as a next-generation pharmaceutical technology. mRNA therapeutics work by delivering genetic instructions that enable cells to produce specific proteins for ...

Approved IV drug reduces lupus symptoms, clinical trial finds

An already-approved IV drug significantly reduces the symptoms of lupus, a new clinical trial showed. More than three-quarters of lupus patients taking obinutuzumab (Gazvya) had a significant improvement in their symptoms ...

How do GLP-1 agonists affect gene expression?

GLP-1s are building a reputation as "wonder drugs." First characterized for their ability to improve insulin release and treat diabetes, the drugs were later found to promote weight loss and improve cardiovascular health. ...

Creating less trippy, more therapeutic 'magic mushrooms'

Psilocybin—the psychoactive compound in "magic mushrooms"—is gaining scientific attention for its potential in treating neuropsychiatric conditions including depression, anxiety, substance use disorders and certain neurodegenerative ...